Is there a link between thrombotic thrombocytopenic purpura and anti-glomerular basement membrane disease?

these unexpected results.We are also questioning about differences in the PB medication among the 11 participating countries.After investigating the reasons for the very low numbers of PB prescription, we strongly suggest a separate analysis of the patients on the basis of the PB medications and the serum phosphate level to understand the association of these parameters with the outcomes.Apart from some particular dialysis schedule including long and/or daily strategies, phosphataemia remains an important marker of nutrition in cases of conventional HD.The use of PBs could be associated with a better outcome when associated with a higher protein intake, but this remains a speculation.We encourage the ARO investigators to provide more observational data from European countries to improve our understanding of the association between mineral metabolism disorders, their treatments and outcomes.